# Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

> **NCT05366855** · PHASE3 · TERMINATED · sponsor: **Vanda Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** Double-blind 200 mg imsidolimab
- **OTHER:** Placebo
- **DRUG:** Open-label 200 mg imsidolimab
- **OTHER:** Standard of Care (SOC)
- **DRUG:** Imsidolimab 750 mg IV/200 mg SC

## Key facts

- **NCT ID:** NCT05366855
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-21
- **Primary completion:** 2024-07-12
- **Final completion:** 2024-07-12
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** AnaptysBio has concluded the GEMINI-2 trial, with all trial participants having been treated with imsidolimab for approximately six months and the furthest subject having been treated through 104 weeks.
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366855, "Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT05366855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*